Last reviewed · How we verify
NCT06373367: PrEPS
Preeclampsia Educational Program Study (PrEPS)
NA trial testing Illustration based application in Preeclampsia in 36 participants. Participants enrolled and being followed up; not accepting new ones.
29 May 2025
Quick facts
| Lead sponsor | MemorialCare Health System |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | other |
| Enrollment | 36 |
| Start date | 1 October 2024 |
| Primary completion | 29 May 2025 |
| Estimated completion | 31 May 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Illustration based application
- Text based application
Conditions studied
- Preeclampsia — all drugs for Preeclampsia →
- Preeclampsia Severe — all drugs for Preeclampsia Severe →
- Preeclampsia Mild — all drugs for Preeclampsia Mild →
- Preeclampsia Postpartum — all drugs for Preeclampsia Postpartum →
Sponsor
MemorialCare Health System — full company profile →
Who can join
18 and older, female only, with Preeclampsia or Preeclampsia Severe. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Preeclampsia complicates approximately 8% of all pregnancies. A critical factor of outpatient monitoring is patient education; specifically, education regarding nature of the disease, ongoing short- and long-term risks, and warning signs and symptoms for worsening of disease. This study aims to compare patient knowledge using a novel illustration based app compared to standard discharge instructions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06373367
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preeclampsia
Currently open trials in the same condition.
- NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
- NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
- NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
- NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
- NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting
Other MemorialCare Health System trials
Trials by the same sponsor.
- NCT06363929 — Continuous Glucose Monitoring in Neonatal Hyperinsulinism · terminated
- NCT05751863 — Analgesia-First Sedation in Trauma Patients · NA · recruiting
- NCT04199676 — Immediate Postpartum Glucose Tolerance Testing · recruiting
- NCT02715921 — Impact of Telerehabilitation Training on Pediatric Cystic Fibrosis Patients: An Exploratory Study · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06373367 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MemorialCare Health System
- Last refreshed: 9 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06373367.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing